Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years' experience of chelation treatment.

Maximova, Natalia; Gregori, Massimo; Simeone, Roberto; Sonzogni, Aurelio; Boz, Giulia; Fucile, Carmen; Marini, Valeria; Martelli, Antonietta; Mattioli, Francesca

Maximova, Natalia; Gregori, Massimo; Simeone, Roberto; Sonzogni, Aurelio; Boz, Giulia; Fucile, Carmen; Marini, Valeria; Martelli, Antonietta; Mattioli, Francesca.

Afiliação

Maximova N; Bone Marrow Transplant Unit, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Gregori M; Department of Pediatric Radiology, Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste, Italy.
Simeone R; University of Trieste, Trieste, Italy.
Sonzogni A; Department of Pathology, Ospedale Beato Papa Giovanni XIII, Bergamo, Italy.
Boz G; University of Cagliari, Faculty of Medicine, Cagliari, Italy.
Fucile C; Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.
Marini V; Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.
Martelli A; Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.
Mattioli F; Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.

Oncotarget ; 8(38): 63177-63186, 2017 Sep 08.

Article em En | MEDLINE | ID: mdl-28968980

Palavras-chave

allogeneic hematopoietic stem cell transplantation (allo-HSCT); deferasirox; ductopenia; pediatric; therapeutic drug monitoring

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google